Assessing Pseudovirus Infection Using Luciferase Reporter Assay
JoVE Encyclopedia of Experiments
Microbiology
0 views • 2:01 min • July 31st, 2026
Begin with a culture of epithelial cells infected with a pseudovirus, which is a genetically engineered non-virulent virus.
The pseudovirus carries a luciferase reporter gene that enables expression of the luciferase enzyme in the infected host cells.
Remove the media from the well.
Wash with a buffer to remove any residual media.
Add a lysis buffer to the well that aids in cell lysis.
Incubate at an ultra-low temperature to freeze the cells.
Thaw the cells at room temperature.
The freezing and thawing process ensures complete cell lysis, releasing intracellular components, including the luciferase enzyme.
Transfer the cell lysate to an opaque plate to reduce the background signal during luminescence measurement.
Add a substrate.
The luciferase enzyme in the lysate reacts with the substrate, emitting light.
Measure the emitted luminescence to quantify the pseudovirus infection level.
To perform the luciferase assay, wash the cells by removing the medium carefully and rinsing it with 200 microliters of PBS.
Remove as much of the PBS as possible, then add 50 milliliters of the lysis buffer to each well. On the next day, equilibrate the plates at room temperature for two hours, then rock the culture plates several times and transfer all the cell lysates to opaque 96 well plates. Add 50 microliters of the substrate to each plate and mix it well.
Record the luciferase titers of the pseudo virus by using the luminometer.
Overview
This article demonstrates a luciferase-based assay to quantify infection by pseudotyped H5 avian influenza viruses in epithelial cells. The protocol utilizes a genetically engineered pseudovirus carrying a luciferase reporter gene, enabling sensitive detection of infection levels through luminescence measurement after cell lysis.
Key Study Components
Area of Science
- Virology
- Cell Biology
- Immunology
Background
- Pseudotyped viruses are non-virulent, genetically engineered viruses used for safe infection studies.
- Luciferase reporter assays provide a quantitative readout of viral infection in host cells.
- Measuring neutralizing antibody activity against avian influenza is important for vaccine and therapeutic development.
- Accurate quantification of infection is essential for evaluating antiviral responses.
Purpose of Study
- To prepare pseudotyped H5 avian influenza viruses using a calcium phosphate transfection method.
- To establish a luciferase-based assay for quantifying pseudovirus infection in epithelial cells.
- To enable measurement of antibody neutralizing activity against the pseudovirus.
Methods Used
- Infection of epithelial cells with luciferase-encoding pseudovirus.
- Removal of media and washing cells with PBS to eliminate residual components.
- Cell lysis using a lysis buffer, followed by freeze-thaw cycles to ensure complete lysis.
- Transfer of lysate to opaque 96-well plates to minimize background signal.
- Addition of luciferase substrate and measurement of luminescence using a luminometer.
Main Results
- The luciferase assay provides a sensitive and quantitative measure of pseudovirus infection in epithelial cells.
- Freeze-thaw lysis ensures efficient release of intracellular luciferase enzyme.
- Opaque plates reduce background and improve signal detection during luminescence measurement.
- The protocol enables assessment of neutralizing antibody activity by comparing luminescence levels.
Conclusions
- The described luciferase-based assay is effective for quantifying pseudovirus infection.
- This method facilitates safe and accurate evaluation of antibody neutralization against H5 avian influenza.
- The protocol can be adapted for similar virological and immunological studies.
Frequently Asked Questions
Executive Industry Relevance
Quantitative luciferase reporter assays for pseudovirus infection provide a robust platform for evaluating viral entry and neutralizing antibody activity in early-stage antiviral and vaccine research. This approach enables predictive confidence in target validation and supports risk-adjusted advancement decisions by delivering reproducible, quantitative infection metrics. The method is directly relevant to portfolio triage and mechanistic de-risking in virology-focused discovery pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables functional validation of viral entry pathways using safe, non-virulent pseudoviruses.
- Supports mechanistic de-risking by quantifying infection in a controlled, reproducible system.
- Facilitates rapid assessment of neutralizing antibody candidates for target engagement.
Screening & Assay Development
- Provides a standardized, quantitative readout for high-throughput screening of antiviral compounds or antibodies.
- Ensures assay reproducibility and scalability through luminescence-based detection.
- Delivers validated infection metrics suitable for downstream screening workflows.
Translational & Preclinical Research
- Aligns with translational biomarker strategies by enabling quantitative comparison of neutralizing activity across candidate molecules.
- Supports continuity from discovery to preclinical validation by providing robust infection data for lead selection.
- Reduces biological risk by enabling early, quantitative go/no-go decisions.
Pipeline & Workflow Integration
This luciferase-based pseudovirus infection assay fits within the early discovery to lead identification continuum, supporting both target validation and screening readiness for antiviral and vaccine programs.
- Discovery Biology: Quantifies infection to test hypotheses about viral entry and antibody neutralization.
- Screening: Provides reproducible, quantitative outputs for compound or antibody evaluation.
- Analytics: Enables direct comparison of infection levels across experimental conditions using luminescence readouts.
- Translational Research: Facilitates alignment with preclinical biomarker strategies by supporting quantitative neutralization assessment.
- Enterprise Reuse: Offers a reusable assay platform adaptable to multiple viral targets and antibody candidates.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation and neutralization efficacy.
- Operational Value: Delivers standardized, scalable, and reproducible infection quantification.
- Strategic Value: Improves go/no-go decision-making and reduces late-stage biological risk.
- Portfolio Impact: Enables risk-adjusted prioritization of antiviral and vaccine candidates.
Implementation Considerations
- Requires expertise in virology, cell culture, and luminescence-based assay operation.
- Needs access to luminometers and opaque 96-well plates for accurate signal detection.
- Demands rigorous cross-team standardization of infection and lysis protocols.
- Adaptable to different pseudovirus systems with appropriate reporter gene engineering.
- Dependent on careful control of background signal and assay conditions for reliable quantification.
Biopharma FAQs
Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
Related Videos
0 Views
Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
Related Videos
0 Views
Pseudotyped Viruses As a Molecular Tool to Monitor Humoral Immune Responses Against SARS-CoV-2 Via Neutralization Assay
Related Videos
0 Views
Determining Optimal Target Cell Density Using a Luciferase-Based Pseudovirus Infection Assay
Related Videos
0 Views
An In Vitro Recombinant Virus Reporter System for the Detection of Viral Infection
Related Videos
0 Views
A Luciferase-Fluorescent Reporter Influenza Virus to Track Viral Infections
Related Videos
0 Views
A Luciferase Reporter Assay to Study Translation Regulation in Poxvirus-Infected Cells
Related Videos
0 Views
High-throughput Titration of Luciferase-expressing Recombinant Viruses
Related Videos
0 Views
Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors
Related Videos
0 Views
In Vitro Transcribed RNA-based Luciferase Reporter Assay to Study Translation Regulation in Poxvirus-infected Cells
Related Videos
0 Views
Last updated: 29 August 2026